NO20003721L - Farmasøytisk aktivt morfolinol - Google Patents

Farmasøytisk aktivt morfolinol

Info

Publication number
NO20003721L
NO20003721L NO20003721A NO20003721A NO20003721L NO 20003721 L NO20003721 L NO 20003721L NO 20003721 A NO20003721 A NO 20003721A NO 20003721 A NO20003721 A NO 20003721A NO 20003721 L NO20003721 L NO 20003721L
Authority
NO
Norway
Prior art keywords
morpholinol
pharmaceutically active
solvates
disease
compound
Prior art date
Application number
NO20003721A
Other languages
English (en)
Other versions
NO20003721D0 (no
NO326878B1 (no
Inventor
Phillip Frederick Morgan
David Lee Musso
John Joseph Partidge
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801230.5A external-priority patent/GB9801230D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20003721D0 publication Critical patent/NO20003721D0/no
Publication of NO20003721L publication Critical patent/NO20003721L/no
Publication of NO326878B1 publication Critical patent/NO326878B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det er beskrevet forbindelsen (+)-(2S,3S)-2-(3-klorofey)-3,,-tty-2-morfolinol og farmasøytisk akseptable salter og solvater derav, farmasøytiske sammensetninger som inneholder disse, og det er også beskrevet en fremgangsmåte for behandling av depresjon, oppmerksomhetredusert hyperaktivitetsforstyrrelse (ADHD), fedme, migrene, smerte, seksuell feilfunksjon, Parkinson sykdom, Alzheimers sykdom eller avhengighet av kokain eller nikotin-inneholdende (spesielt tobakk) produkter ved anvendelse av en slik forbindelse, salter, solvater eller sammensetninger.
NO20003721A 1998-01-21 2000-07-20 Anvendelse av morfolinol NO326878B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9801230.5A GB9801230D0 (en) 1998-01-21 1998-01-21 Pharmaceutically active morpholinol
US7218098P 1998-01-22 1998-01-22
PCT/US1999/001134 WO1999037305A1 (en) 1998-01-21 1999-01-20 Pharmaceutically active morpholinol

Publications (3)

Publication Number Publication Date
NO20003721D0 NO20003721D0 (no) 2000-07-20
NO20003721L true NO20003721L (no) 2000-09-19
NO326878B1 NO326878B1 (no) 2009-03-09

Family

ID=26312986

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20003721A NO326878B1 (no) 1998-01-21 2000-07-20 Anvendelse av morfolinol
NO20083529A NO20083529L (no) 1998-01-21 2008-08-14 Farmasoytisk aktivt morfolinol

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20083529A NO20083529L (no) 1998-01-21 2008-08-14 Farmasoytisk aktivt morfolinol

Country Status (30)

Country Link
US (2) US6274579B1 (no)
EP (2) EP1047428B1 (no)
JP (1) JP2002501025A (no)
KR (1) KR100568063B1 (no)
CN (2) CN1203858C (no)
AP (1) AP1229A (no)
AT (1) ATE365042T1 (no)
AU (1) AU755536B2 (no)
BR (1) BR9907203A (no)
CA (1) CA2318268A1 (no)
CY (1) CY1106828T1 (no)
DE (1) DE69936335T2 (no)
DK (1) DK1047428T3 (no)
EA (1) EA002410B1 (no)
EE (1) EE04452B1 (no)
ES (1) ES2288012T3 (no)
HR (2) HRP20051024A2 (no)
HU (1) HUP0100900A3 (no)
ID (1) ID26334A (no)
IL (2) IL161942A0 (no)
IS (1) IS2494B (no)
NO (2) NO326878B1 (no)
NZ (3) NZ520349A (no)
PL (1) PL193622B1 (no)
PT (1) PT1047428E (no)
SG (1) SG115489A1 (no)
SK (1) SK10912000A3 (no)
TR (1) TR200002126T2 (no)
WO (1) WO1999037305A1 (no)
YU (1) YU67102A (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
AU2349999A (en) * 1998-01-29 1999-08-16 Sepracor, Inc. Pharmacological uses of pure (+) -bupropion
US6855820B2 (en) 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
EP1220673A2 (en) * 1999-10-13 2002-07-10 Glaxo Group Limited Morpholinol derivatives for the treatment of obesity
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US7145649B2 (en) * 2000-12-21 2006-12-05 Brasscorp Limited Method of producing an ultra-violet or near ultra-violet light source for non-destructive inspection or testing
US6979104B2 (en) 2001-12-31 2005-12-27 R.J. Doran & Co. LTD LED inspection lamp
EP3173082A1 (en) 2002-05-17 2017-05-31 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
WO2004017977A2 (en) * 2002-08-23 2004-03-04 Eli Lilly And Company 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
US20070093486A1 (en) * 2003-10-27 2007-04-26 Smith Kline Beecham Corporation ,Corporation Enzyme-catalyzed dynamic kinetic resolution process for preparing (+)-(2s,3s)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinoland salts and solvates thereof
GB0325055D0 (en) * 2003-10-27 2003-12-03 Smithkline Beecham Corp New process
GB0326148D0 (en) * 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
GB0327619D0 (en) * 2003-11-27 2003-12-31 Smithkline Beecham Corp New use
US7429580B2 (en) * 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
RU2006139930A (ru) * 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
FI117283B (fi) 2005-02-04 2006-08-31 Kone Corp Hissijärjestelmä
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
CA2635261A1 (en) * 2006-01-03 2007-07-12 Algebra, Inc. Therapeutic amine-arylsulfonamide conjugate compounds
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
TWI609702B (zh) 2006-11-09 2018-01-01 歐瑞根治療有限公司 層狀醫藥調配物
US20090075994A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched radafaxine
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
EP2419400A1 (en) 2009-04-15 2012-02-22 Research Triangle Institute Monoamine reuptake inhibitors
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
JP2013526583A (ja) 2010-05-21 2013-06-24 リサーチ・トライアングル・インスティチュート フェニルモルホリンおよびその類似体
CA2800219C (en) 2010-05-21 2019-03-12 Research Triangle Institute 1 - phenylmorpholine derivatives as hydroxybupropion analogues for treating drug dependence
US9510405B2 (en) 2011-06-30 2016-11-29 Schneider Electric Industries Sas Dual power SMPS for a modular lighting system
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
CN105949142B (zh) * 2016-05-21 2018-03-27 南华大学 具有抗抑郁活性的单一手性化合物及其制备方法和应用
RU2763728C1 (ru) * 2021-06-17 2021-12-30 Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) Применение 3-(2-(4-нитрофенил)-2-оксоэтилиден)морфолин-2-она в качестве средства, обладающего противомикробной активностью

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US170430A (en) * 1875-11-30 Improvement in furnaces for heating steel in tempering
GB8417170D0 (en) * 1984-07-05 1984-08-08 Wellcome Found Heterocyclic pharmaceutical compounds
GB9108629D0 (en) 1991-04-23 1991-06-12 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use

Also Published As

Publication number Publication date
YU67102A (sh) 2004-12-31
JP2002501025A (ja) 2002-01-15
HUP0100900A3 (en) 2002-08-28
AP1229A (en) 2003-12-04
IS2494B (is) 2009-02-15
HRP20000494A2 (en) 2000-12-31
EE04452B1 (et) 2005-04-15
WO1999037305A1 (en) 1999-07-29
AU755536B2 (en) 2002-12-12
CN1255389C (zh) 2006-05-10
DK1047428T3 (da) 2007-10-08
BR9907203A (pt) 2000-10-17
CN1294513A (zh) 2001-05-09
HUP0100900A2 (hu) 2002-05-29
ID26334A (id) 2000-12-14
TR200002126T2 (tr) 2000-12-21
EA002410B1 (ru) 2002-04-25
AP2000001869A0 (en) 2000-09-30
SK10912000A3 (sk) 2001-04-09
EP1829544A1 (en) 2007-09-05
KR20010034285A (ko) 2001-04-25
IL161942A0 (en) 2005-11-20
US6274579B1 (en) 2001-08-14
CA2318268A1 (en) 1999-07-29
ATE365042T1 (de) 2007-07-15
US6391875B2 (en) 2002-05-21
EP1047428A1 (en) 2000-11-02
EA200000691A1 (ru) 2001-04-23
SG115489A1 (en) 2005-10-28
AU2328099A (en) 1999-08-09
CN1203858C (zh) 2005-06-01
US20020019396A1 (en) 2002-02-14
CN1528753A (zh) 2004-09-15
IL137346A0 (en) 2001-07-24
HRP20051024A2 (hr) 2006-04-30
NZ529316A (en) 2004-05-28
EP1047428A4 (en) 2001-12-19
ES2288012T3 (es) 2007-12-16
HRP20000494B1 (en) 2009-02-28
NZ520349A (en) 2004-02-27
NO20083529L (no) 2000-09-19
EP1047428B1 (en) 2007-06-20
KR100568063B1 (ko) 2006-04-07
NZ505809A (en) 2002-09-27
DE69936335T2 (de) 2008-02-28
DE69936335D1 (de) 2007-08-02
PT1047428E (pt) 2007-09-07
CY1106828T1 (el) 2012-05-23
NO20003721D0 (no) 2000-07-20
PL342012A1 (en) 2001-05-07
NO326878B1 (no) 2009-03-09
PL193622B1 (pl) 2007-02-28
EE200000438A (et) 2001-12-17
IS5568A (is) 2000-07-20

Similar Documents

Publication Publication Date Title
NO20003721L (no) Farmasøytisk aktivt morfolinol
MY163027A (en) FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-(α) ASSOCIATED DISORDERS
HUP0104258A2 (hu) HMG-CoA reduktáz inhibítort tartalmazó stabil gyógyszerkészítmények
JP2002501025A5 (no)
BR9917007A (pt) Moduladores de ccr5
DK0678023T3 (da) Anvendelse af riluzol ved fremstilling af lægemidler til behandling af Parkinsons sygdom og parkinsonisme-syndromer
NO20063373L (no) CD40-antistoff-formuleringer og fremgangsmater
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
RU94022479A (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат
EP1177798A3 (en) A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder(ADHD) comprising a nicotine receptor partial agonist and anti-ADHD agent
ATE273693T1 (de) Proteinhaltige arzneimittel
ATE412407T1 (de) Arzneimittel zubereitung enthaltend 2-amino-2-ä2- (4-octylphenyl)ethylüpropane-1,3-diol, ein lecithin und ein saccharid
EP1050301A4 (en) Medicinal compositions
SE9603725D0 (sv) New teatment
ATE277907T1 (de) Blutzuckersenkende und lipidsenkende verbindungen
MY117960A (en) A new salt
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
SE9800905D0 (sv) New therapy in glomerulonephritis
NO20062970L (no) 7-[4-(4-klorobenzyloksy)benzensulfonyl]-8-metoksy-3-metyl-2,3,4,5-tetrahydro-1 H-3-benzazepiniummaleat eller tosyslat som antipsykotia
YU46300A (sh) Farmaceutski aktivni morfolinol
HUP0103544A2 (hu) (R)-3-(N,N-diciklobutil amino)-8-fluor-3,4dihidro-2H-1-benzopirán-5karboxamid-hidrogén-(2R,3R)tartarát monohidrátot és paroxelint tartalmazó gyógyszerkészítmény és eljárás az előállítására
SE0102886D0 (sv) New formulation
SE0102888D0 (sv) New formulation
NO20040471L (no) 5,6,6a,1 1b-tetrahydro-7-oksa-5-azabenzo[c]fluoren-6-karboksylsyrederivater som NMDA-antagonister

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees